Zinzino Reports 20% Revenue Growth in July 2026, Driven by North America and Central Europe
Event summary
- Zinzino's group revenue increased by 20% year-over-year to SEK 315.9 million in July 2026.
- Faun Pharma's external sales rose by 14% to SEK 2.5 million.
- Year-to-date (January–July) revenue grew by 22% to SEK 2,174.8 million.
- North America and Central Europe showed the highest growth at 36% and 28%, respectively.
- East Europe and The Baltics experienced declines of 1% and 13%, respectively.
The big picture
Zinzino's strong performance in July 2026 highlights its expanding footprint in key markets, particularly North America and Central Europe. The company's ability to leverage these regions while mitigating declines in others will be critical for maintaining its growth trajectory. The strategic integration of Faun Pharma's sales could further bolster Zinzino's position in the healthcare and direct selling sectors.
What we're watching
- Geographic Expansion
- How Zinzino will sustain growth in high-performing regions like North America and Central Europe while addressing declines in East Europe and The Baltics.
- Market Dynamics
- Whether the 388% surge in South America and 71% increase in Asia-Pacific indicate long-term market potential or short-term anomalies.
- Operational Efficiency
- The pace at which Zinzino can integrate Faun Pharma's growth into its overall strategy to drive consistent revenue increases.